📰 Validive Phase News

Validive Phase News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Validive Phase. Real-time updates on events, politics, business and more.

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

August 10, 2023

Camsirubicin Phase 1b Trial Currently at 5th Dose-Level , Generating Encouraging ResultsMNPR-101 Radiopharma Program Advancing Toward First-in-Human Studies WILMETTE, Ill., Aug. 10, 2023 --... -Today at 07:03 am- MarketScreener

Anand Jeyasekharan Kimr Tsuchimoto Promisingpreclinicaldataignitefurther Research Radiopharma Program Advancing Toward Northstar Medical Radioisotopes Cancer Science Institute

Source: marketscreener.com

Dow Rises 50 Points; Harmony Biosciences Shares Plunge

March 28, 2023

U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 50 points on Tuesday. The Dow traded up 0.16% to 32,484.24 whi...

City Of United Kingdom Mark Bertolini Dan Hart Excelerate Energy Inc Oscar Health Inc

Source: businessinsider.com

Nasdaq Dips 90 Points; Walgreens Posts Upbeat Q2 Results

March 28, 2023

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around&nbsp;90 points on Tuesday. The Dow traded down 0.21...

City Of United Kingdom Dan Hart Mark Bertolini Harmony Biosciences Holdings Inc Granite Ridge Resources Inc

Source: businessinsider.com

Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

March 27, 2023

WILMETTE, Ill., March 27, 2023 -- Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the... | March 27, 2023

Monopartx Linkedin Kimr Tsuchimoto Chandler Robinson Exchange Commission Monopar Therapeutics Inc Validive Phase

Source: marketscreener.com

Monopar Therapeutics Inc.: Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis

October 5, 2022

Interim Analysis Planned for Q1 2023WILMETTE, Ill., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary

Chandler Robinson Kimr Tsuchimoto Exchange Commission Monopar Therapeutics Inc Interim Analysis Planned Validive Phase

Source: finanznachrichten.de

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science

Navigation